Laboratorios Sophia S.A de C.V.
45
2
2
31
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 35/100
20.0%
9 terminated/withdrawn out of 45 trials
77.5%
-9.0% vs industry average
38%
17 trials in Phase 3/4
97%
30 of 31 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (45)
Comparative Study of the Efficacy of Either Krytantek Ofteno PF® or Eliptic Ofteno PF® Plus Gaap Ofteno PF® for POAG or Ocular Hypertension.
Role: lead
Study Evaluating PRO-232 an Ophthalmic Solution Compared to Placebo.
Role: lead
Evaluation of Manzanilla® and Meticel Ofteno® 0.5% for Providing a Relief Sensation to the Eyes
Role: lead
Clinical Study to Evaluate PRO-169 for Diabetic Macular Edema
Role: lead
Safety and Immunogenicity of PRO-169 in Patients With Diabetic Macular Edema
Role: lead
Phase II Clinical Study to Evaluate the Efficacy of Multidose Lagricel® Ofteno Ophthalmic Solution as Treatment for Dry Eye Disease.
Role: lead
Study to Compare the Efficacy of the Ophthalmic Solution Humylub Ofteno® PF With Hyabak® and Lagricel Ofteno® PF as Treatment for Dry Eye.
Role: lead
Phase I Clinical Trial to Evaluate the Safety and Tolerability of Ophtalmic Solution PRO-201
Role: lead
Safety and Tolerability of the Ophthalmic Gel PRO-165 Versus Artelac® Nightime Gel
Role: lead
PRO-232 in Patients Subjected to Cataract Surgery
Role: lead
Study to Evaluate the Safety of the Viscoelastic Substance PRO-149, Compared to Healon® EndoCoat.
Role: lead
Safety and Tolerability of PRO-185
Role: lead
Clinical Study for the Evaluation of Safety and Tolerability of PRO-172 Ophthalmic Solution+
Role: lead
Clinical Trial to Compare the Safety and Efficacy of Nanodrop®
Role: lead
Study to Evaluate the Safety and Tolerability of PRO-231 Versus VIGAMOXI® on the Ocular Surface of Healthy Subjects
Role: lead
Study to Evaluate the Efficacy of Alleance® (Atropine Sulfate 0.01%) as a Treatment to Delay Myopia and Axial Ocular Elongation in Children.
Role: lead
Study to Evaluate the Safety and Tolerability of PRO-190 Ophthalmic Solution Compared to Systane Ultra® on the Ocular Surface.
Role: lead
Study to Evaluating PRO-240 Ophthalmic Solution Compared to Optive®
Role: lead
PRO-122 Versus Concomitant Therapy in Subjects With Uncontrolled Primary Open-angle Glaucoma (PRO-122LATAM)
Role: lead
Clinical Study to Evaluate the Safety and Tolerability of PRO-229 Ophthalmic Solution Compared to Lagricel® Ofteno PF
Role: lead